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DISCUSSION AND CONCLUSIONS 
Graphic 1. Differences on identification of BMAA showing that not always results are positive. Ref. [6]   
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Neurodegenerative diseases are disorders of the central nervous system that result from the selective and premature atrophy of functionally related neurons.  
Although each of these diseases has early-onset familial forms, the vast majority of cases are sporadic, supporting the notion that environmental factors can be an important 
cause of neurological disorders although this fact is usually undervalued. 
 
Cyanobacteria are a phylum of photosynthetic bacteria characteristic for cyanobacterial blooms formation, their ubiquity and their ability to produce a wide range of potent 
hepatotoxins, neurotoxins, cytotoxins and inflammatory agents which can affect public health. 
 
Although most articles talk about BMAA as a neurotoxin produced by members of all five cyanobacterial sections including symbionts and free-living as well, some articles refuse 
this idea and affirm that since this non-protein amino acid has antiherbivory properties, it should take part as a component produced by plants.  
 
Moreover, some authors have linked BMAA with amyotrophic lateral sclerosis (ALS), Alzheimer’s disease (AD) and Parkinson’s disease (PD) and diverse experiments in vitro as 
well as in vivo have been made in order to demonstrate it, while others deny this hypothesis owing to non detection BMAA having been reported in their studies.  
RESULTS 
a) Experiments in order to know if cyanobacteria produce the neurotoxin BMAA  
b) Experiments so as to determine if BMAA is one possible cause of neurodegenerative diseases:  
 
- Most studies seem to indicate that cyanobacteria produce BMAA in spite of negative results. Possible explanations for the striking variations in BMAA concentrations could be 
the variance in the range of BMAA content between genera and species and also within the ratio of free to protein-bound BMAA suggests that BMAA production and storage 
depends on growth conditions and life cycle stages.  
 
- All results seem to indicate that BMAA cause neurodegeneration but divergence in opinions is still evident. A possible explanation for the variations on presence / absence of 
BMAA in the same tissue could be attributed to the use of different animal models and the level of impact and susceptibility of each specie. Differences in the pharmacokinetics 
and distribution of BMAA or the need of longer time of exposure may be crucial to observe neurological deficits. Other factors that should influence are the analysis with different 
methods that yield diverse results, specially when using a non-selective method or others that are not as sensitive, and last but not least, not revising the works.  
 
- An animal model of chronic BMAA toxicity is needed, not only to prove the concept of the hypothesis but also to provide a test-bed for developing therapeutic strategies. 
 
- Discovering that BMAA is produced by diverse taxa of cyanobacteria and their ubiquity, suggests that exposure to BMAA may be more widespread than previously believed and 
that it is necessary a severe control in order to prevent diseases.  
Table 1. BMAA is produced by diverse taxa of cyanobacteria in free living as well as symbionts. Ref. [4]   
Graphic 2.Observation of BMAA depending on growth conditions. Ref. [5]   
Figure 3. Biomagnification of BMAA into Guam ecosystem. 
 Ref. [1]  
The aim of this work is to review: if cyanobacteria produce the neurotoxin BMAA and if this non-protein amino acid is actually a possible cause of neurodegenerative diseases 
When cyanobacteria stay in symbiosis with Cycas, 
the neurotoxin is localized on the sarcotesta of 
seeds.  Flying foxes as well as other animals fed on 
these seeds bioaccumulate BMAA into their tissues 
increasing that concentration. When Chamorro 
people eat this flying foxes they biomagnificate the 
toxin into their brain and develop the disease.  
If this chain didn’t exist, BMAA  wouldn’t cause 
neurological dysfunctions because there aren’t 
enough doses in the environment to cause disease.  
Table 3. Analysis post-mortem of  
brain from people who died as a 
consequence of neurological 
diseases. Ref . [1] 
Despite in most 
articles BMAA 
is found in 
cyanobacterial 
cultures, there 
are some 
studies that 
have not 
provided 
conclusive 
evidence of it 
because 
different 
methods were 
used, or they 
may contain 
errors  due to a 
lack of critical 
discussions 
and revision.  
Free living 
cyanobacteria 
produce less 
doses of BMAA 
than when stay in 
symbiosis with 
collaroid roods.  
Moreover, 
concentration of 
BMMA in protein 
form is higher 
than free form.   
In this experiment has been demonstrated that BMAA 
is produced in axenic cyanobacterial culture with 
deprivation of nitrogen. It is suggest that BMAA is 
produced by cyanobacteria and that it may have a 
function in nitrogen metabolism .  
• At a dose of 150 mg/kg:  
morphology of the hippocampus, 
striatum, and substantia nigra did 
not differ from control (B and E). 
•At a dose of 460 mg/kg:  
neuronal loss, accompanied by 
astrogliosis(F), and remaining 
neurons were degenerating or 
necrotic, several neurons 
contained a granular, faintly 
greenish, birefringent material 
(C) and presence of calcium 
deposits (M) was demonstrate.   
 
Figure 4. Direct histological observations of hippocampal sections of adult 
rats neonatally treated with different doses of  BMAA. Ref. [7]  
Levels of BMAA present in brain 
tissue of people who died due to 
neurodegenerative diseases is a 
relevant evidence that this 
neurotoxin is strictly related with 
this type of pathologies.  
However, BMAA was not 
detected in HD patients and the 
bond between BMAA and all 
types of neurodegeneratives can 
be rejected.  
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Figure 3. misincorporation of BMAA 
into proteins. Ref. [10] 
If non-protein amino acid is 
mistaken for an essential 
amino acid during protein 
formation it can be 
incorporated into proteins and 
alter tertiary folding. This 
mistake leads to an increase 
of protein aggregation. Then 
an endogenous reservoir is 
created that releases free-
BMAA over time. This BMAA 
serve as agonist at 
neuroreceptor and cause 
latency periods and 
neurological chronic diseases. 
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 Figure 1. Modes of action of BMAA in neurons. Ref. [2]  
Graphic 3. Impact induced by different BMAA’s concentrations on spinal neurons and motor 
neurons. Ref. [8]   
When BMAA is present as a β-carbamate it can bind to NMDA, 
AMPA and mGlu receptors. This activation results in an increase 
of Na+ and Ca2+ and a decrease of K+ channeling the release of  
ROS. Cell becomes depolarized and leads to the permeability of 
the cell membrane and the release of noradrenalin. BMAA also 
inhibits the cysteine/glutamate antiporter system Xc- resulting in 
glutathione depletion which contributes to rises in oxidative 
stress. System Xc- also increases extracellular glutamate which 
can then bind glutamate receptors and extend the damage by 
excitotoxicity. 
Finally, cytochrome-c is released from the mitochondria resulting 
in the induction of apoptosis. 
Motor neurons (MN) are 
more susceptibility to low 
concentrations of BMAA 
than other neurons. BMAA 
triggers considerable 
damage in MN while 
leaving spinal neurons 
relatively uninjured. This 
fact is related to the 
pattern of selective 
neuronal loss seen in ALS   
Table 2. A chronological summary of mechanisms of BMAA activity in vivo. Ref. [2]  
Table 3. A chronological summary of mechanisms of BMAA activity in vitro. Ref. [2]  
Results show a strong relation between biochemical and neuronal functions changes depending 
on the diverse doses of BMAA and exposure times.    
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